Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free Strategy.

ABSTRACT:

Background

Safety of proton pump inhibitors (PPIs) in patients undergoing percutaneous coronary intervention (PCI) with aspirin-free P2Y₁₂ inhibitor monotherapy was unknown.

Objectives

The authors aimed to evaluate effects of PPIs in patients undergoing PCI with P2Y₁₂ inhibitor monotherapy.

Methods

We compared outcomes between patients with and without PPI prescription in the STOPDAPT-3 trial enrolling patients undergoing PCI stratified by the no-aspirin (1-month prasugrel monotherapy followed by clopidogrel monotherapy: n = 2,909 [acute coronary syndrome: n = 2,170, high bleeding risk: n = 1,580]) and the aspirin (1-month dual antiplatelet therapy followed by aspirin monotherapy: n = 2,914 [acute coronary syndrome: n = 2,171, high bleeding risk:

SUBMITTER: Nishikura T 

PROVIDER: S-EPMC12904821 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature